AbbVie Inc. (NYSE:ABBV) had its price target lifted by Jefferies Group LLC from $107.00 to $115.00 in a report published on Monday. Jefferies Group LLC currently has a buy rating on the stock.

Several other analysts have also recently issued reports on ABBV. Societe Generale upgraded AbbVie from a hold rating to a buy rating in a report on Thursday, June 22nd. Leerink Swann restated a market perform rating on shares of AbbVie in a report on Thursday, June 22nd. Zacks Investment Research cut AbbVie from a hold rating to a sell rating in a report on Tuesday, July 4th. Vetr upgraded AbbVie from a hold rating to a buy rating and set a $74.86 target price for the company in a report on Thursday, July 6th. Finally, Deutsche Bank AG reaffirmed a hold rating and issued a $66.00 price target (up previously from $65.00) on shares of AbbVie in a research note on Monday, July 17th. Eight research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $92.25.

Shares of AbbVie (NYSE:ABBV) opened at 91.04 on Monday. The company has a market capitalization of $145.13 billion, a P/E ratio of 22.39 and a beta of 1.51. AbbVie has a 12 month low of $55.06 and a 12 month high of $92.61. The company has a 50-day moving average price of $85.49 and a 200-day moving average price of $72.96.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 28th. The company reported $1.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.40 by $0.02. The company had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The firm’s quarterly revenue was up 7.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.26 EPS. On average, analysts forecast that AbbVie will post $5.53 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/10/17/abbvie-inc-abbv-price-target-increased-to-115-00-by-analysts-at-jefferies-group-llc.html.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be paid a dividend of $0.64 per share. This represents a $2.56 annualized dividend and a yield of 2.81%. The ex-dividend date of this dividend is Thursday, October 12th. AbbVie’s payout ratio is 62.90%.

In other AbbVie news, VP Robert A. Michael sold 6,699 shares of the stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $88.00, for a total value of $589,512.00. Following the sale, the vice president now owns 10,007 shares of the company’s stock, valued at approximately $880,616. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Henry O. Gosebruch sold 18,000 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $70.09, for a total value of $1,261,620.00. Following the completion of the sale, the insider now directly owns 96,074 shares in the company, valued at approximately $6,733,826.66. The disclosure for this sale can be found here. In the last three months, insiders have sold 379,890 shares of company stock worth $27,187,817. 0.23% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Acropolis Investment Management LLC acquired a new stake in AbbVie in the 2nd quarter valued at about $106,000. Ffcm LLC raised its position in AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after purchasing an additional 963 shares in the last quarter. Hudock Capital Group LLC raised its position in AbbVie by 109.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after purchasing an additional 806 shares in the last quarter. BDO Wealth Advisors LLC acquired a new stake in AbbVie in the 2nd quarter valued at about $115,000. Finally, Franklin Parlapiano Turner & Welch LLC acquired a new stake in AbbVie in the 1st quarter valued at about $108,000. 68.25% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.